HCD, HCP, and Mycoplasma: Key Quality Control Considerations in Biopharmaceutical Manufacturing

From cell substrate to final product, effective impurity and contamination control is essential for biologic safety, consistency, and regulatory readiness.

Biopharmaceutical manufacturing depends on living cells, complex biological materials, and highly integrated purification processes. That complexity creates a fundamental quality challenge: how do you ensure that the final product contains what you want—and as little of what you do not want as possible?

Among the many quality attributes monitored throughout biologics development and manufacturing, three areas deserve particular attention:

• Host Cell DNA (HCD) — residual nucleic acid from the production cell substrate
• Host Cell Protein (HCP) — residual proteins originating from the host cell
• Mycoplasma — a difficult-to-detect microbial contaminant that can compromise cell cultures and manufacturing processes

These are not simply final-product testing requirements. They are components of a broader control strategy spanning cell banks, upstream processing, downstream purification, analytical testing, and final product release. 

Figure 1. Comprehensive Risk and Control Landscape in Biopharmaceutical Process Quality Control 

1. Host Cell DNA: Controlling Residual Genetic Material

Biologics can be produced using host systems such as CHO, HEK293, Vero, E. coli, and yeast. During cell growth and processing, host-cell DNA can be released into the process stream and must be effectively removed during downstream purification.

Residual DNA is important from both product safety and process-control perspectives. Its amount, size, and source may all be relevant to product characterization and risk assessment.

How is residual DNA detected?

qPCR is widely used because of its sensitivity, specificity, and throughput. ddPCR can provide absolute quantification and may be useful for challenging low-level samples, while DNA-binding fluorescence assays can support broader process monitoring.

Table 1. Comparison of Main Detection Methods for HCD (Host Cell DNA)

At low residual levels, sample preparation can directly affect analytical performance. Efficient recovery, removal of matrix interference, and consistent sample processing are therefore important considerations for residual DNA workflows.

2. Host Cell Protein: From Total HCP to Individual Proteins

Host Cell Protein (HCP) represents a complex mixture of proteins originating from the production host. Unlike a single defined impurity, the HCP profile can vary with the host cell, culture conditions, and manufacturing process.

This complexity makes HCP control particularly challenging.

Residual HCP may contribute to immunogenicity, affect product stability or activity, or indicate insufficient downstream clearance.

Complementary HCP Detection Strategies

HCP ELISA remains a widely used approach for quantitative HCP analysis because of its sensitivity and throughput. However, assay performance depends on antibody coverage of the relevant HCP population.

LC-MS provides complementary information by enabling identification and characterization of individual HCPs without relying on antibody recognition.

Table 2. Comparison of Main Detection Methods for HCP (Host Cell Proteins)

Method	Principle	Strength	Limitation	Typical Use
ELISA	Polyclonal sandwich	Sensitive, high-throughput, quantitative	Coverage-dependent; no single-HCP ID	Lot release (preferred), validation
LC-MS/MS	Proteolytic peptides, MS ID	Single-HCP ID; no antibody needed	Costly; complex data analysis	HCP profiling, orthogonal verification
Western Blot	SDS-PAGE + immuno-blot	Molecular-weight ID	Semi-quantitative; low throughput	Supportive identification
2D Electrophoresis	pI + MW separation	Visualizes full HCP profile	Low throughput; limited repeatability	Early development (superseded by LC-MS)

For process development and higher-risk applications, combining routine ELISA testing with orthogonal LC-MS characterization can provide a more comprehensive view of HCP clearance.

3. Mycoplasma: A Contamination Risk That Can Stay Hidden

Unlike HCD and HCP, Mycoplasma is an adventitious microbial contaminant.

Mycoplasma can persist in cell cultures without obvious signs of contamination. Even when cultures appear normal, infection can alter cell growth, metabolism, and protein expression, potentially compromising both process performance and product quality.

Potential sources include:

• Cell banks and cell lines
• Raw materials and biological reagents
• Personnel and handling
• Equipment and laboratory environments
• Detection: Culture and NAT

Traditional culture-based methods can detect viable Mycoplasma but require a long testing period. Nucleic acid amplification testing (NAT/qPCR) provides a much faster alternative when appropriately validated.

Table 3. Comparison of Main Detection Methods for Mycoplasma

A robust Mycoplasma strategy therefore combines prevention, routine monitoring, and appropriately validated detection methods.

Building an Integrated QC Strategy

HCD, HCP, and Mycoplasma should not be treated as isolated testing requirements.

A more effective approach connects prevention, process control, sample preparation, analytical testing, and release testing throughout the manufacturing lifecycle.

Table 4. Overview of Core Elements for the Three Critical Impurities

HCD, HCP, and Mycoplasma represent different risks, but all three require more than a single end-point test.

A robust biopharmaceutical QC strategy integrates:

Prevention → Process Control → Sample Preparation → Sensitive Detection → Orthogonal Verification

The goal is not simply to demonstrate that a batch passes testing. It is to build a manufacturing process that consistently produces high-quality biologics with well-understood and controlled risks.

Better Process Understanding. More Reliable QC. Greater Confidence in Biopharmaceutical Quality.

Related Products

References

[1] WHO Technical Report Series No. 978. Recommendations for the evaluation of animal cell cultures as substrates for the manufacture of biological medicinal products and for the characterization of cell banks. 2012.

[2] ICH Q6B. Specifications: Test Procedures and Acceptance Criteria for Biotechnological/Biological Products.

[3] Drexler HG, Uphoff CC. Mycoplasma contamination of cell cultures: Incidence, sources, effects, detection, elimination, prevention. Cytotechnology. 2002;39:75-90.

[4] U.S. FDA. Chemistry, Manufacturing, and CMC Considerations for Human Gene Therapy Investigational New Drug Applications.

[5] U.S. Pharmacopeia. General Chapter <63>, Mycoplasma Tests.

[6] U.S. Pharmacopeia. General Chapter <77>, Mycoplasma Nucleic Acid Amplification Tests.

[7] European Directorate for the Quality of Medicines & HealthCare. Revised Ph. Eur. Chapter 2.6.7, Mycoplasmas.